What is the fair value of Genmab AS (NASDAQ-GMAB) stock?

The current fair value estimate for Genmab AS (NASDAQ-GMAB) is $26.54. This implies an estimated downside of 23.6% versus the current market price.

Is Genmab AS (NASDAQ-GMAB) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 23.6% versus the current market price.

What is the analyst price target for NASDAQ-GMAB stock?

The available analyst price target for Genmab AS (NASDAQ-GMAB) is $39.14. The analyst target implies estimated upside of 12.7%.

How is the financial health of Genmab AS?

The current financial health read for Genmab AS (NASDAQ-GMAB) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Genmab AS's next earnings date?

The next earnings date currently listed for Genmab AS (NASDAQ-GMAB) is November 5, 2026.

Does Genmab AS (NASDAQ-GMAB) pay dividends?

The latest available data indicates no current dividend yield for Genmab AS (NASDAQ-GMAB).

What is the P/E ratio for Genmab AS (NASDAQ-GMAB)?

The current P/E ratio listed for Genmab AS (NASDAQ-GMAB) is 26.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Genmab AS?

The current market capitalization listed for Genmab AS is 20.751 B.

What is the enterprise value of Genmab AS?

The current enterprise value listed for Genmab AS is 24.534 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Genmab AS?

The ticker symbol for Genmab AS is NASDAQ-GMAB, and the stock is listed on NASDAQ.

Where is Genmab AS (NASDAQ-GMAB) listed?

Genmab AS (NASDAQ-GMAB) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Genmab AS?

The current debt-to-total-capital ratio listed for Genmab AS is 20.4%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Genmab AS?

The free float listed for Genmab AS is 98.8%. Free float helps investors understand how much of the share base is available for public trading.

Genmab AS (GMAB) Fair Value & Stock Analysis

Genmab AS (GMAB)

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, and the NASDAQ-listed instrument is a depositary receipt representing its common stock. The company focuses on antibody-based medicines and product candidates for cancer and other serious diseases. Its commercial portfolio includes EPKINLY and TEPKINLY for certain B-cell lymphomas, and Tivdak for recurrent or metastatic cervical cancer. Genmab is also advancing a broad development pipeline that includes therapies for multiple lymphoma settings, solid tumors, non-small cell lung cancer, ovarian cancer, advanced solid tumors, multiple sclerosis, thyroid eye disease, sickle cell disease, and hemophilia A. In addition, it has collaboration agreements with AbbVie, Pfizer, BioNTech, Johnson & Johnson, Medarex, Bristol Myers Squibb, Lundbeck, Amgen, Novo Nordisk, and argenx.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-GMAB	$26.54	-23.6% Downside	Overvalued	$39.14	12.7% Upside	Fair	Great	0.0%	November 5, 2026	26.3x	3.5x	5.0x	20.751 B	24.534 B	20.4%	98.8%	14.6	110.3%